(800) 424-6690

Submit Your Information for the
RxSight Lawsuit

Lead plaintiff deadline is September 22, 2025.

If you purchased or acquired RxSight securities between November 7, 2024 and July 8, 2025, please contact Berger Montague using the form below.

First Name

Last Name

Email

Phone Number

Address

City

Zip

State

Are you a current or former employee of RxSight?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

Please view our terms of use policy and our privacy policy.

About the RxSight Lawsuit

The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight’s products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.

On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that “[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.”

On this news, RxSight shares fell $4.84, or 37%, to a close of $7.95 per share on July 9, 2025.

Investors who purchased or acquired RxSight securities between November 7, 2024 and July 8, 2025, may no later than September 22, 2025, seek to be appointed as a lead plaintiff representative of the class.